|Podcasts|September 30, 2021
Episode 92: Digesting the GI Market
Author(s)Elaine Quilici, Miranda Schmalfuhs
Tom McCourt, CEO of Ironwood Pharmaceuticals, talks about his 30-plus years in the gastrointestinal space, including his experiences bringing top GI medicines Prilosec, Nexium, Entocort, Zelnorm, and Linzess to market.
Advertisement
Tom McCourt, CEO of Ironwood Pharmaceuticals, discusses his extensive background in gastrointestinal drug development, the current landscape of therapies, and what the future may hold for this space.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
AI has Redefined Healthcare Communication — and There’s No Opting Out
2
Novo Nordisk Signs Deal with Hims & Hers
3
Mergers and Acquisitions Roundup: GSK and Alfasigma Enter Licensing Agreement for Linerixibat, Servier Enters $2.5 Billion Definitive Agreement to Acquire Day One Pharmaceuticals
4
How FDA's Removal of the Two-Trial Requirement Affects Development Programs
5